Business Context and Reporting Period
Universe Pharmaceuticals INC, a Cayman Islands exempted company with principal executive offices in Ji'an, Jiangxi, China, filed this Form 6-K on April 16, 2026. The report covers the month of April 2026 and details the adoption of a new equity incentive plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity plan adoption rather than financial performance.
Material Changes
On April 14, 2026, the Company adopted the "2026 Equity Incentive Plan." This represents a material change in the Company's compensation structure designed to attract and retain personnel and align their interests with shareholders.
Guidance, Outlook, and Plan Details
- Purpose: To attract and retain key personnel and promote long-term business success.
- Award Types: Includes incentive share options, non-statutory share options, share appreciation rights, restricted shares, restricted share units, performance units, performance shares, and other share-based awards.
- Share Reserve: A maximum of 84,500 ordinary shares (Class A, Class B, or a combination) are available for issuance under the plan.
- Automatic Increase: Beginning January 2027, the share reserve will automatically increase annually by 10% of the total ordinary shares issued and outstanding as of the last trading day of the preceding year, subject to Board determination and authorized share capital.
- Eligibility: Employees, directors, and consultants of the Company and its subsidiaries. Incentive share options are restricted to employees only.
- Ownership Limit: No award may be granted if it would cause a director or officer to hold more than 75% of the total combined voting power.
- Term: Options granted under the plan may not exceed 10 years from the grant date.
Investor Verification Checklist
- Verify the full text of the 2026 Equity Incentive Plan attached as Exhibit 10.1 for specific vesting schedules and performance metrics.
- Confirm the current total number of ordinary shares issued and outstanding to calculate the potential automatic increase in the share reserve starting in 2027.
- Review the Company's authorized share capital to ensure it can accommodate the initial 84,500 shares and future automatic increases.
- Monitor future filings for the actual grant of awards under this new plan and the associated dilution impact.